Cure My Disease

Don't miss your cure!

 Log in / Sign up

Experimental drug aims to quiet gut inflammation in ulcerative colitis

NCT ID NCT06420375

Recruiting now Disease control Sponsor: Brigham and Women's Hospital Source: ClinicalTrials.gov ↗

First seen Jul 21, 2026 · Last updated Jul 22, 2026 · Updated 1 time

Summary

This trial tests an experimental oral drug called BRS201 in people with active mild ulcerative colitis. Participants take the drug or a placebo for four weeks each in a crossover design, and researchers measure changes in gut inflammation markers and symptoms. The study involves 20 participants and lasts 12 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
an experimental drug called BRS201
What this could lead to
If successful, this could point toward a new treatment option for people with mild ulcerative colitis.
What could go wrong
This is a small, early-phase trial with only 20 participants, so results may not apply to everyone. The drug may not reduce inflammation or improve symptoms significantly.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ULCERATIVE COLITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ulcerative colitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ULCERATIVE COLITIS ULCERATIVE COLITIS MILD

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Brigham and Women's Hospital

    RECRUITING

    Chestnut Hill, Massachusetts, 02467, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.